X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs WOCKHARDT LTD. - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA WOCKHARDT LTD. DISHMAN PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 25.1 -15.9 - View Chart
P/BV x 3.3 2.6 128.6% View Chart
Dividend Yield % 0.7 1.3 52.4%  

Financials

 DISHMAN PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
WOCKHARDT LTD.
Mar-17
DISHMAN PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs3741,129 33.2%   
Low Rs129627 20.6%   
Sales per share (Unadj.) Rs197.8363.1 54.5%  
Earnings per share (Unadj.) Rs21.2-20.4 -103.7%  
Cash flow per share (Unadj.) Rs34.7-7.0 -497.8%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.81.1 69.8%  
Book value per share (Unadj.) Rs179.9301.8 59.6%  
Shares outstanding (eoy) m80.69110.55 73.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.32.4 52.6%   
Avg P/E ratio x11.9-42.9 -27.6%  
P/CF ratio (eoy) x7.2-125.9 -5.8%  
Price / Book Value ratio x1.42.9 48.1%  
Dividend payout %9.4-48.9 -19.3%   
Avg Mkt Cap Rs m20,30697,063 20.9%   
No. of employees `0000.86.8 12.2%   
Total wages/salary Rs m5,3559,665 55.4%   
Avg. sales/employee Rs Th19,252.75,931.8 324.6%   
Avg. wages/employee Rs Th6,459.51,428.1 452.3%   
Avg. net profit/employee Rs Th2,064.1-334.0 -618.0%   
INCOME DATA
Net Sales Rs m15,96140,146 39.8%  
Other income Rs m2651,143 23.2%   
Total revenues Rs m16,22641,289 39.3%   
Gross profit Rs m4,103128 3,205.6%  
Depreciation Rs m1,0911,489 73.2%   
Interest Rs m9442,253 41.9%   
Profit before tax Rs m2,334-2,472 -94.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624-211 -295.4%   
Profit after tax Rs m1,711-2,260 -75.7%  
Gross profit margin %25.70.3 8,063.2%  
Effective tax rate %26.78.5 312.9%   
Net profit margin %10.7-5.6 -190.4%  
BALANCE SHEET DATA
Current assets Rs m11,01846,160 23.9%   
Current liabilities Rs m9,51719,258 49.4%   
Net working cap to sales %9.467.0 14.0%  
Current ratio x1.22.4 48.3%  
Inventory Days Days110101 109.7%  
Debtors Days Days3594 37.0%  
Net fixed assets Rs m16,30440,165 40.6%   
Share capital Rs m161553 29.2%   
"Free" reserves Rs m12,90732,814 39.3%   
Net worth Rs m14,51633,367 43.5%   
Long term debt Rs m4,18931,903 13.1%   
Total assets Rs m29,80589,687 33.2%  
Interest coverage x3.5-0.1 -3,573.6%   
Debt to equity ratio x0.31.0 30.2%  
Sales to assets ratio x0.50.4 119.6%   
Return on assets %8.90 -103,775.7%  
Return on equity %11.8-6.8 -174.0%  
Return on capital %17.5-0.3 -5,229.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9529,121 54.3%   
Fx outflow Rs m6972,133 32.7%   
Net fx Rs m4,2556,988 60.9%   
CASH FLOW
From Operations Rs m2,786-2,695 -103.4%  
From Investments Rs m-1,529-6,863 22.3%  
From Financial Activity Rs m-94112,545 -7.5%  
Net Cashflow Rs m3163,010 10.5%  

Share Holding

Indian Promoters % 61.4 74.5 82.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 2.3 160.9%  
FIIs % 12.7 7.7 164.9%  
ADR/GDR % 0.0 0.1 -  
Free float % 22.1 15.4 143.5%  
Shareholders   46,261 67,757 68.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  CIPLA  TORRENT PHARMA  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS